At last, a conservative news aggregator that does not bow to the woke right.
In this RedState article, Carole Dykhouse argues that critics are ignoring major drug-price reductions tied to TrumpRx because they would rather defend government-heavy healthcare narratives than acknowledge results from President Trump’s negotiation-based approach.
- Dykhouse pushes back against a Daily Kos critique claiming TrumpRx.gov is not lowering drug prices as Trump has stated.
- The article cites several examples of lower prices listed through TrumpRx, including Pristiq dropping from $435 to $200 and Ngenla dropping from $4,434 to $2,217.
- Other examples include Xeljanz falling from $2,277 to $1,518 and Orencia SC dropping from $6,070 to $3,660.
- Dykhouse argues that even frequent Trump critic Mark Cuban has endorsed the effort, suggesting the price reductions are difficult to dismiss on partisan grounds.
- The piece frames TrumpRx as a market-oriented alternative to expanding bureaucracy, saying it achieved savings through private-sector cooperation rather than new government programs.
- The article says Trump negotiated with major pharmaceutical companies, including Pfizer, Eli Lilly, and Novo Nordisk, while also using tariff threats and domestic manufacturing incentives as leverage.
- Pfizer is cited as describing its arrangement as a “voluntary agreement with the U.S. government.”
- Dykhouse argues the broader lesson is that aggressive negotiation from the presidency can produce consumer benefits without relying on what she portrays as socialist mandates.
- The article says Trump announced an expansion of the website this month to include more than 600 generic drugs.
Read the full story: https://redstate.com/redstate-guest-editorial/2026/05/30/why-cant-hyper-partisans-admit-trumprx-is-dramatically-slashing-drug-costs-n2202849
